Home
Pharmathen

Pharmathen Market Share Analysis for November 2025

Pharmathen is a research-centered, pharmaceutical company which focuses in developing innovative generic products. Pharmathen is providing a complete package of integrated services including finished products, know-how, and technological and regulatory support to its partners worldwide.

Health > Biotechnology and Pharmaceuticals

Domainpharmathen.com

Year Founded1969

Employees1001 - 5000

Annual Revenue$200M - $500M

Pharmathen

Pharmathen (including company regionals)

pharmathen.com

See more website traffic and engagement information

Pharmathen Revenue up to November 2025 is 200M - 500M

revenue generated by Pharmathen top domains

Pharmathen top domains revenue over 3 years

Revenue for Pharmathen top domains

pharmathen.com200M - 500M

See more with Sales Intelligence

Total visits to Pharmathen's top domains

Understand Pharmathen market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

pharmathen.com2.6K

See more with Sales Intelligence

Avg. visit duration in Pharmathen's top domains

Analyze Pharmathen engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

pharmathen.com00:00:13

See more with Sales Intelligence

Avg. pageviews on Pharmathen's top domains

See how Pharmathen keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

pharmathen.com1.80

See more with Sales Intelligence

Pharmathen top competitors by domain

Top similar sites in November 2025, ranked by their affinity

ppdi.comCompany NamePPDEmployees> 10001HQUnited States, North Carolina, WilmingtonAnnual revenue> $1BTotal visits46.7KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Pharmathen

These are the website technologies, by industry, used by Pharmathen top domains

Advertising (4)

DoubleClick

Content Management System (3)

Drupal

Marketing (3)

Google Marketing Platform

Widget (3)

Google Maps

More Technologies

9

See all

News & Signals from Pharmathen

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsPharmathen Group is developing long-acting injectable therapies for the psychiatry sector.Neuraxpharm and Pharmathen have signed a co-development agreement to develop long-acting injectable (LAI) therapies for the psychiatry sector.

NewsPharmathen Group invested into Sterling Pharma Solutions Limited. $1.72B on Jun 30th '23.The buyout fund bought Greece-based generics manufacturer Pharmathen in 2021 for €1.6bn including debt and last year invested alongside GHO in drug manufacturing outsourcer Sterling Pharma Solutions.

NewsPharmathen Group expands facilities to Greece.Pharmathen has developed one of the most advanced pipelines of long-acting injectables (LAI), sustained-release oral solids and ophthalmic formulations, produced in its US-FDA and EU-approved manufacturing facilities in Greece.